Sandhill One

Sandhill One is a private, early-stage biotech founded in 2020 by pharmaceutical industry veterans to address vulnerabilities in traditional drug supply chains. The company's proprietary technology platform uses plant-derived starting materials, catalysis, and synthetic biology to create efficient, cost-effective, and secure synthetic pathways for APIs that historically relied on variable animal or natural sources. By focusing on supply chain innovation rather than novel drug discovery, Sandhill One aims to provide more reliable and accessible production of existing, critical medicines while positioning itself as a strategic supplier to the pharmaceutical industry.

A hybrid chemistry and synthetic biology platform that uses plant-derived starting materials and catalysis to create efficient, non-animal-derived synthetic routes for pharmaceutical intermediates and APIs.

Competition includes large, traditional API manufacturers and CDMOs that may use conventional methods, as well as other synthetic biology startups targeting bio-based production of chemicals and materials. Sandhill One's niche focus on replacing animal-derived drug sources with a hybrid chemistry-biology approach is a specific differentiator.